title: [Pergolide associated valvulopathy: critical analysis of the literature and practical recommendations].
abstract: BACKGROUND
  Pergolide is a widely used antiparkinsonian dopamine agonist. Following occasional case reports, two studies recently suggested potentially frequent and severe valvular disease associated with pergolide intake.
  
  
  BACKGROUND
  Although there is now strong evidence to consider that pergolide may induce valvulopathy, incidence, severity, and risk factors for this adverse effect remain to be clarified. Valvular disease associated with pergolide consists in fibrosis and resembles conditions described in carcinoid carcinoma and in patients taking fenfluramine therapy. The mechanisms leading to valvular fibrosis are unknown but involvement of 5-HT(2B) receptors, especially expressed in valvular fibroblasts, is suspected.
  
  
  CONCLUSIONS
  Following the recommendations of the Agence Française de Sécurité Sanitaire des Produits de Santé, we describe a clinical practice attitude for pergolide therapy in Parkinson's disease.
authors.affiliation: Centre d'Investigation Clinique et Fédération des Maladies du Système Nerveux, Hôpital de la Pitié-Salpêtrière, Paris. Jean-Christophe.corvol@psl.ap-hop-paris.fr
authors.forename: J-C
authors.initials: JC
authors.lastname: Corvol
authors.forename: M
authors.initials: M
authors.lastname: Schüpbach
authors.forename: A-M
authors.initials: AM
authors.lastname: Bonnet
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D010479:Pergolide / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000978:Antiparkinson Agents; D010479:Pergolide